HomeMYGN • NASDAQ
Myriad Genetics Inc
$12.67
Makalipas ang Oras ng Trabaho:
$12.70
(0.24%)+0.030
Sarado: Ene 31, 8:00:00 PM GMT-5 · USD · NASDAQ · Disclaimer
StockSegurong nakalista sa USMay headquarter sa US
Nakaraang pagsara
$12.91
Sakop ng araw
$12.51 - $13.09
Sakop ng taon
$12.04 - $29.30
Market cap
1.15B USD
Average na Volume
1.07M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
(USD)Set 2024Y/Y na pagbabago
Kita
213.30M11.15%
Gastos sa pagpapatakbo
167.60M4.68%
Net na kita
-22.10M63.95%
Net profit margin
-10.3667.56%
Kita sa bawat share
0.06300.00%
EBITDA
-2.20M87.36%
Aktuwal na % ng binabayarang buwis
-4.25%—
Kabuuang asset
Kabuuang sagutin
(USD)Set 2024Y/Y na pagbabago
Cash at mga panandaliang investment
99.90M15.76%
Kabuuang asset
1.08B-5.90%
Kabuuang sagutin
349.60M-24.93%
Kabuuang equity
731.70M—
Natitirang share
91.04M—
Presyo para makapag-book
1.61—
Return on assets
-4.11%—
Return on capital
-5.06%—
Net change in cash
(USD)Set 2024Y/Y na pagbabago
Net na kita
-22.10M63.95%
Cash mula sa mga operasyon
700.00K103.17%
Cash mula sa pag-invest
7.50M400.00%
Cash mula sa financing
-3.10M-24.00%
Net change in cash
8.60M131.05%
Malayang cash flow
16.28M148.95%
Tungkol
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
Itinatag
1991
Website
Mga Empleyado
2,700
Search
I-clear ang paghahanap
Isara ang paghahanap
Mga app ng Google
Pangunahing menu